ANTI-B1 (MURINE) IN CHEMOTHERAPY-REFRACTORY LOW GRADE NONHODGKIN'S LYMPHOMA

化疗难治性低度非霍奇金淋巴瘤中的抗 B1（鼠）抗体

• 批准号: 6115044
• 负责人: Susan J. Knox
• 金额: $ 4.03万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6115044
• 关键词: B cell lymphoma; CD antigens; clinical research; clinical trials; drug adverse effect; human subject; human therapy evaluation; longitudinal human study; monoclonal antibody; neoplasm /cancer immunotherapy; neoplasm /cancer radionuclide therapy; nonHodgkin's lymphoma; radiation dosage

This is a multicenter prospectively randomized study between 131 Iodine- Anti-B1 RIT and unlabeled Anti-B1 monoclonal antibody therapy for patients with chemotherapy-refractory low-grade B-cell lymphomas. The objectives of this study are to assess the incremental clinical activity and toxicity of radiolabeling murine monoclonal Anti-CD20 antibody (Anti-B1) with 131 Iodine as compared to unlabeled Anti-B1 inpatients with relapsed low-grade non-Hodgkin's lymphome (NHL) in a controlled and randomized trial. This study is being conducted in patients with chemotherapy-refractory (doxorubicin-resistant or alkylator-resistant) low-grade NHL who have progessed within one year after completing the last chemotherapy regimen. Patients treated with 131 I-Anti-B1 first receive an infusion of unlabeled Anti-B1 immediately followed by an infusion of Anti-B1 which has been trace lableled with 5 mCi of 131I. The radiation dose to the whole body delivered by the tracer dose over approximately one week is calculated from the radioactivity clearance data. Based upon these calculations specific for each individual patient, a RIT dose of 131 I-Anti-B1 is given so that a whole body radiation does of 75 cGy is delivered. In the unlabeled antibody arm, patients will receive an equivalent amount of unlabeled B1. Partial one-way crossover to the Anti-B1 RIT arm will be possible for patients treated with unlabeled Anti-B1 following progression of the disease. This treatment with radiolabeled Anti-B1 will also allow for comparison of responses in the same patient treated with both labeled and unlabeled Anti-B1. Response in both arms will be assessed after six weeks, after 12 weeks and in 12 weekly intervals thereafter up to two years following enrollment of the last patient. Crossover can take place up to 21 months following the enrollment of the last patient.

这是一项多中心前瞻性随机研究